Skip to main content

Table 2 The proportion (%) of bloodstream infection (BSI) episodes with microbe(s) non-susceptible to some common antibiotic regimens

From: Trends in antimicrobial resistance and empiric antibiotic therapy of bloodstream infections at a general hospital in Mid-Norway: a prospective observational study

  Total 2002–2005a 2006–2009 2010–2013 p for trend
Penicillin-gentamicin
 Total 6.1 4.4 6.1 7.5 0.011
 Community acquired 4.3 2.2 5.7 5.0 0.22
 Health care-associated 6.7 7.4 5.8 7.2 0.16
 Hospital acquired 10.2 4.4 8.6 16.5 0.023
 p for trend 0.006 0.058 0.46 0.003  
Penicillin-gentamicin-metronidazole
 Total 3.5 1.9 3.0 5.2 <0.001
 Community acquired 1.4 0.3 1.8 2.1 0.28
 Health care-associated 4.8 4.6 3.2 6.3 0.045
 Hospital acquired 6.9 2.2 6.2 11.7 0.026
 p for trend <0.001 0.007 0.15 0.001  
Piperacillin/tazobactam
 Total (n = 1413) 7.6   7.4 7.7 0.25
 Community acquired (n = 617) 3.6   2.9 4.2 0.27
 Health care-associated (n = 612) 8.8   9.4 8.4 0.31
 Hospital acquired (n = 184) 8.8   9.4 17.0 0.31
 p for trend <0.001   <0.001 <0.001  
Piperacillin/tazobactam-gentamicin
 Total (n = 1413) 3.0   2.4 3.6 0.21
 Community acquired (n = 617) 1.0   0.7 1.2 0.69
 Health care-associated (n = 612) 3.3   3.2 3.3 0.98
 Hospital acquired (n = 184) 9.2   4.9 12.6 0.12
 p for trend <0.001   0.037 <0.001  
Piperacillin/tazobactam-gentamicin-metronidazole
 Total (n = 1413) 2.6   1.7 3.4 0.065
 Community acquired (n = 617) 0.5   0.0 0.9 0.26
 Health care-associated (n = 612) 2.9   2.5 3.3 0.64
 Hospital acquired (n = 184) 8.7   4.9 11.7 0.12
 p for trend <0.001   0.004 <0.001  
Imipenem
 Community acquired 1.1 1.6 0.7 0.9 0.59
 Health care-associated 6.5 9.1 5.8 5.7 0.39
 Hospital acquired 10.6 11.1 7.4 12.6 0.14
 p for trend <0.001 <0.001 0.001 <0.001  
Cefotaxime
 Total 17.8 17.5 18.7 17.3 0.68
 Community acquired 10.8 11.0 11.4 10.1 0.69
 Health care-associated 21.3 25.1 22.7 18.2 0.18
 Hospital acquired 31.4 25.6 29.6 37.9 0.31
 p for trend <0.001 <0.001 <0.001 <0.001  
Ceftazidime
 Total 27.8 29.0 24.8 29.4 0.25
 Community acquired 18.5 20.2 15.4 19.6 0.42
 Health care-associated 31.3 36.0 28.2 31.3 0.37
 Hospital acquired 49.6 46.7 45.7 55.3 0.46
 p for trend <0.001 <0.001 <0.001 <0.001  
  1. aPiperacillin/tazobactam was not adopted in the first time period
  2. The BSIs are stratified by place of acquisition and by time period (the total number in each cell is shown under the heading Place of acquisition in Table 1)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us